Asiatic Laboratories Limited (ASIATICLAB)
A
| Pharmaceuticals & Chemicals
INTRADAY 1MIN CHART
Loading ...
Price: -
Volume: -
Today Analysis
Asiatic Laboratories Limited এর শেয়ারটি 103.80 BDT-এ লেনদেন হচ্ছে, যা বর্তমান ট্রেন্ডে পতনের দিকে। কোম্পানিটির NAV 54.08 BDT-এ অবস্থান করছে, যা দীর্ঘমেয়াদী বিনিয়োগের জন্য একটি নির্দেশক হিসেবে কাজ করে। কোম্পানির P/E Ratio নির্দেশ করে এটি তুলনামূলকভাবে আয়ের চেয়ে কতগুণ বেশি মূল্যে লেনদেন হচ্ছে। টেকনিক্যাল এনালাইসিস অনুযায়ী, সাপোর্ট লেভেল 100.69 BDT-এর কাছাকাছি হতে পারে, যেখানে শেয়ারটি ঘুরে দাঁড়াতে পারে। অন্যদিকে 107.43 BDT-এ একটি সম্ভাব্য রেজিস্ট্যান্স আছে, যেখানে দাম বাধা পেতে পারে। বিনিয়োগের সিদ্ধান্ত নেওয়ার আগে, মার্কেটের সামগ্রিক অবস্থা ও কোম্পানির ফান্ডামেন্টালগুলো বিবেচনা করা জরুরি।
(Disclaimer: This system generated summary is for informational purposes only and does not constitute financial advice.)
Market Depth (Live Order Book)
Buy Orders (Bids)
| Cum Qty | Volume | Price |
|---|---|---|
| No buy orders | ||
Sell Orders (Asks)
| Price | Volume | Cum Qty |
|---|---|---|
| No sell orders | ||
| Date | Close | Volume | Trade | Change | Ch(%) | Open | High | Low |
|---|---|---|---|---|---|---|---|---|
| Loading historical data... | ||||||||
30 Apr, 2026
ASIATICLAB: Q3 Financials
(Q3 Un-audited): EPS was Tk. 1.39 for January-March 2026 as against Tk. 0.75 for January-March 2025; EPS was Tk. 3.97 for July 2025-March 2026 as against Tk. 1.71 for July 2024-March 2025. NOCFPS was Tk. 5.73 for July 2025-March 2026 as against Tk. 1.73 for July 2024-March 2025. NAV per share with revaluation surplus was Tk. 57.46 as on March 31, 2026, and Tk. 54.08 as on June 30, 2025; NAV per share without revaluation surplus was Tk. 44.25 as on March 31, 2026, and Tk. 40.85 as on June 30, 2025. (cont.)
22 Apr, 2026
ASIATICLAB: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 3:30 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
05 Feb, 2026
ASIATICLAB: Q2 Financials
(Q2 Un-audited): EPS was Tk. 1.34 for October-December 2025 as against Tk. 0.72 for October-December 2024; EPS was Tk. 2.58 for July-December 2025 as against Tk. 0.96 for July-December 2024. NOCFPS was Tk. 4.01 for July-December 2025 as against Tk. 0.87 for July-December 2024. NAV per share with revaluation surplus was Tk. 56.07 as on December 31, 2025 and Tk. 54.08 as on June 30, 2025. NAV per share without revaluation surplus was Tk. 42.85 as on December 31, 2025 and (cont.1)
05 Feb, 2026
ASIATICLAB: Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.
02 Feb, 2026
ASIATICLAB: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on February 04, 2026 at 5:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
05 Jan, 2026
ASIATICLAB: Credit Rating Result
WASO Credit Rating Company (BD) Ltd. has awarded the Surveillance entity rating of the Company as "BBB" for long term and "ST 3" for short term along with Stable outlook based on updated audited financial statement of FY2025 (30.06.2025) and other relevant qualitative and quantitative information.
07 Dec, 2025
ASIATICLAB: Regarding AGM Venue of the company
Refer to their earlier news disseminated by DSE on 02.11.2025 regarding dividend declaration, the company has further informed that the Annual General Meeting of the company will be held on the selected venue at EON Convention Center, 304, Bir Uttam Mir Shawkat Sarak, Tejgaon I/A, Dhaka-1208 (Besides of Channel I Head Office and Impulse Hospital) as well as virtually by using Digital Platform through the link: https://asiaticlab2025.hybridagmbd.net.
20 Nov, 2025
ASIATICLAB: Resumption after Record Date
Trading of the shares of the company will resume on 23.11.2025.
19 Nov, 2025
ASIATICLAB: Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 20.11.2025.
17 Nov, 2025
ASIATICLAB: Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 18.11.2025 to 19.11.2025 and trading of the shares will remain suspended on record date i.e., 20.11.2025.
11 Nov, 2025
ASIATICLAB: Q1 Financials
(Q1 Un-audited): EPS was Tk. 1.24 for July-September 2025 as against Tk. 0.24 for July-September 2024; NOCFPS was Tk. 2.02 for July-September 2025 as against Tk. 0.60 for July-September 2024. NAV per share was Tk. 55.33 (with revaluation surplus) and Tk. 42.10 (without revaluation surplus) as on September 30, 2025, and Tk. 54.08 (with revaluation surplus) and Tk. 40.85 (without revaluation surplus) as on June 30, 2025. Significant deviation in EPS, NAVPS and NOCFPS: (cont.1)
06 Nov, 2025
ASIATICLAB: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 10, 2025 at 5:30 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
02 Nov, 2025
ASIATICLAB: Price Limit Open
There will be no price limit on the trading of the shares of the Company today (02.11.2025) following its corporate declaration.
02 Nov, 2025
ASIATICLAB: Dividend Declaration
The Board of Directors has recommended 10% Cash dividend for all Shareholders excluding Directors and Sponsors for the year ended June 30, 2025. The Directors and Sponsors who shall not be entitled to the recommended Cash Dividend, hold 49,828,490 shares out of total 122,393,455 shares. The total amount of Cash Dividend to be payable to the General Shareholders and Independent Directors and only is Tk. 72,564,965.00 for 72,564,965 nos of ordinary shares. (cont.)
23 Oct, 2025
ASIATICLAB: Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 30, 2025 at 4:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2025
28 Sep, 2025
ASIATICLAB: Board approval for construction of 32 storied high-tech building
The company has informed that the Board of Directors in its meeting held on September 27, 2025 unanimously approved the construction of a new 32-storied high-tech building (name Time Square - Dhaka) will be constructed at 159/A. Tejgaon Commercial Area, Dhaka. The construction of the building will be on 20 katha land. (cont.)
19 Aug, 2025
ASIATICLAB: Query Response
In response to the DSE query dated August 17, 2025, the company has informed via a letter received today i.e., August 19, 2025 that there is no undisclosed price sensitive information of the company for recent unusual price hike and increase in volume of shares.
19 Aug, 2025
ASIATICLAB: Non-response to DSE's query on hike in price and volume of shares
This is for the information of all concerned that DSE sent a query letter regarding unusual hike in price and volume of shares to Asiatic Laboratories Limited on August 17, 2025. However, the company has not provided any response yet.
29 Apr, 2025
ASIATICLAB: Q3 Financials
(Q3 Un-audited): EPS was Tk. 0.75 for January-March 2025 as against Tk. 0.59 for January-March 2024; EPS was Tk. 1.71 for July 2024-March 2025 as against Tk. 2.26 for July 2023-March 2024. NOCFPS was Tk. 1.73 for July 2024-March 2025 as against Tk. 2.06 for July 2023-March 2024. NAV per share with Revaluation was Tk. 53.71 as on March 31, 2025 and Tk. 52.58 as on June 30, 2024. NAV per share without Revaluation was Tk. 40.46 as on March 31, 2025 and Tk. 39.31 as on June 30, 2024. (cont.1)
22 Apr, 2025
ASIATICLAB: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2025 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
16 Feb, 2025
ASIATICLAB: Q2 Financials
(Q2 Un-audited): EPS was Tk. 0.72 for October-December 2024 as against Tk. 0.62 for October-December 2023. EPS was Tk. 0.96 for July-December 2024 as against Tk. 1.54 for July-December 2023. NOCFPS was Tk. 0.87 for July-December 2024 as against Tk. 1.19 for July-December 2023. NAV per share (with revaluation surplus) was Tk. 52.95 as on December 31, 2024 and Tk. 52.58 as on June 30, 2024. NAV per share (without revaluation surplus) was Tk. 39.70 as on December 31, 2024 (cont.1)
10 Feb, 2025
ASIATICLAB: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on February 13, 2025 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
05 Feb, 2025
ASIATICLAB: Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase the securities of Asiatic Laboratories Limited in between 1st to 7th trading days following the change of categorization, with effect from today i.e., February 05, 2025 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
05 Feb, 2025
ASIATICLAB: Category Change
The Company has been placed in 'A' category from existing 'Z' category with effect from today i.e., February 05, 2025 as the Company has reported disbursement of 10% Cash Dividend for the year ended June 30, 2024.
05 Feb, 2025
ASIATICLAB: Dividend Disbursement
The company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
29 Jan, 2025
ASIATICLAB: Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase securities of Asiatic Laboratories Limited with effect from today i.e., 29.01.2025 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
29 Jan, 2025
ASIATICLAB: Category Change
The Company has been placed in 'Z' category from existing 'N' category with effect from today i.e., 29.01.2025 as per provision 1(e) of BSEC Directive No. BSEC/CMRRCD/2009-193/77, dated May 20, 2024 regarding non-disbursement of the approved dividend within the stipulated time frame.
01 Dec, 2024
ASIATICLAB: Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.24 for July-September 2024 as against Tk. 0.92 for July-September 2023; NOCFPS was Tk. 0.60 for July-September 2024 as against Tk. 0.74 for July-September 2023. NAV per share with revaluation surplus was Tk. 52.82 as on September 30, 2024 and Tk. 52.58 as on June 30, 2024. NAV per share without revaluation surplus was Tk. 39.56 as on September 30, 2024 and Tk. 39.31 as on June 30, 2024.
26 Nov, 2024
ASIATICLAB: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 30, 2024 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
20 Nov, 2024
ASIATICLAB: Resumption after Record date
Trading of the shares of the company will resume on 21.11.2024.
19 Nov, 2024
ASIATICLAB: Suspension for record date
Trading of the shares of the company will remain suspended on record date i.e., 20.11.2024.
17 Nov, 2024
ASIATICLAB: Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 18.11.2024 to 19.11.2024. Trading of the shares of the company will remain suspended on record date i.e., 20.11.2024.
31 Oct, 2024
ASIATICLAB: Price Limit Open
There will be no price limit on the trading of the shares of the Company today (31.10.2024) following its corporate declaration.
31 Oct, 2024
ASIATICLAB: Dividend Declaration
The Board of Directors has recommended No Dividend for the year ended June 30, 2023. Date of AGM: 19.12.2024, Time: 11:00 AM, Venue: Hybrid System. Record Date: 20.11.2024. The Company has also reported EPS of Tk. 2.19, NAV per share with revaluation surplus of Tk. 64.48, NAV per share without revaluation surplus of Tk. 45.94 and NOCFPS of Tk. 3.97 for the year ended June 30, 2023 as against Tk. 3.06, Tk. 59.68, Tk. 38.61 and 3.70 respectively for the year ended June 30, 2022.
23 Oct, 2024
ASIATICLAB: Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 30, 2024 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
Total Records: 4 Years
| Year | Type | Cash(%) | Stock(%) | EPS | NAV | Remarks |
|---|---|---|---|---|---|---|
| 2025 | Final | 10.00% | - | 2.09 | 54.08 | 02-Nov-2025 |
| 2024 | Final | 10.00% | - | 2.82 | 52.58 | 31-Oct-2024 |
| 2023 | Final | - | - | 2.19 | 64.48 | 31-Oct-2024 |
| 2022 | Final | - | - | - | - | - |
30-Day Block Transactions
| Date | Max Price | Min Price | Trades | Quantity | Value (Mn) |
|---|---|---|---|---|---|
| 2026-10-06 | 114.00 | 114.00 | 1 | 131,500 | 14.991 |
| 2026-10-05 | 100.20 | 96.60 | 2 | 12,100 | 1.187 |
| 2026-10-04 | 106.50 | 95.10 | 4 | 81,000 | 8.216 |
| 2026-09-29 | 111.00 | 111.00 | 1 | 28,300 | 3.141 |
| 2026-09-28 | 118.00 | 118.00 | 1 | 10,352 | 1.222 |
| 2026-09-23 | 115.90 | 114.00 | 2 | 35,000 | 3.999 |
| 2026-09-22 | 115.00 | 115.00 | 1 | 5,300 | 0.610 |
| 2026-09-16 | 113.00 | 112.00 | 2 | 221,000 | 24.858 |
| 2026-09-15 | 102.00 | 102.00 | 1 | 11,000 | 1.122 |
| 2026-09-13 | 114.00 | 108.00 | 3 | 109,630 | 12.450 |
| 2026-09-10 | 116.60 | 110.00 | 3 | 65,255 | 7.464 |
Company Info
Trading Code
ASIATICLAB
Category : Sector
A : Pharmaceuticals & Chemicals
NAV
54.08 Tk.
P/E Audited
51.82
Paid up Capital
1,223.93 crore
Authorized Capital
2,000.00 crore
Market Capital
12,924.75 crore
Total Securities
122,393,455
Reserve & Surplus
3,197.12 crore
Current Shareholding
Public Holding: 5.42 Cr unit
Public: 44.26% (5.42 Cr unit)
Director: 40.71% (4.98 Cr unit)
Institute: 15.03% (1.84 Cr unit)
Foreign: 0.00% (0.00 Cr unit)
Govt: 0.00% (0.00 Cr unit)
EPS History
NAV History
Dividend History
Cash Dividend
Stock Dividend
Historical Monthly Performance
Compare cumulative monthly performance.
Best Month
-
Worst Month
-
Avg MoM
-
Positive
-
Positive Yrs
-
Historical Insight
-
Historical Seasonality
Holding Period Returns
Entry → Exit Analysis
Entry Month:
Select an entry month to view historical holding period outcomes.
* Historical performance is not indicative of future results. Historical calculations are based on past closing prices and do not constitute investment advice. Dividends are not included.
| Period Ending: |
2022
07/10/2026
|
2023
07/10/2026
|
2024
07/10/2026
|
2025
07/10/2026
|
|---|---|---|---|---|
| Total Revenues | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Gross Profit | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Operating Expenses | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Operating Income | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Pre-tax Income | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Net Income | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| EBITDA | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| EPS (Basic) | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Cash & Equivalents | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Current Assets | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Assets | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Current Liabilities | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Liabilities | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Debt | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Equity | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Cash from Operations | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Cash from Investing | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Cash from Financing | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Capital Expenditure | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Free Cash Flow | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Net Change in Cash | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
Unlock Full Financial Data
Upgrade to PRO to access complete historical financial statements, quarterly reports, and deep fundamental analysis.
Upgrade to PROAsiatic Laboratories Limited
A | Pharmaceuticals & Chemicals
Today-
15 dys-
30 dys-
3 mths-
6 mths-
1 yr-
LTP:-
Open:-
High:-
Low:-
YCP:-
Vol:-
52W H:-
52W L:-
Crct Lw:-
Circuit Up:-
Value:-
M. Cap:-
P/E (Un/A):-
EPS:-
NAV:-
Paid-up:-
Ttl Share:-
Yr end:-
Reserve:-
ROE:-
EPS Q2-
EPS Q3-
EPS ANN-
EPS Q1-
DIV-
DIV YIELD-
Last AGM: -
Record Date: -
Shareholding
(as on -)
Public
0%
Director
0%
Institute
0%
Foreign
0%
Govt.
0%
Market Overview
Loading Data...
(%)
Day Open
Total Trade
Day High
Total Volume
Day Low
Value (Cr)
MARKET STATUS
Up
Down
Unchanged
All Instruments
| Symbol | LTP | Chg% |
|---|---|---|
| Loading... | ||
Sectors
| Sector | Chg% |
|---|---|
| Loading... | |
Stock Screener
Quick Screens
| Symbol | LTP | PE |
|---|---|---|
| Run filter to see results | ||
Alerts
Favorites
Watchlists
Portfolio
My Screeners
| Symbol | LTP | PE |
|---|
Run filter to see results
Market Movers
| # | Symbol | LTP | Chg% |
|---|---|---|---|
| Loading... | |||
AI Insights
Business Pro user exclusive
Login to see